Table 6.
Evidence overview of transurethral prostate convective radiofrequency water vapor (Rezūm system) versus sham
| Outcome | Number of trials (evaluated) | Intervention | Control | Absolute risk difference (95% CI) | Relative risk (95% CI) | Quality of evidence |
|---|---|---|---|---|---|---|
| % (n/N) or mean change | % (n/N) or mean change | |||||
| Responders, based on IPSS reduction of ≥8 points | No data long term | |||||
| IPSS, mean change from baseline: long-term follow-up (>12 mo) | No data long term | |||||
| IPSS, mean change from baseline: long-term follow-up (>12 mo) | No data long term | |||||
| Need for reoperation | 1 (197) | <1 (1/135) | 0 (0/61) | 0.7% (–2.1 to 3.6) | 1.4 (0.1–33.0) | Very lowa |
| Transfusion | NR | |||||
| Urinary incontinence | NR |
CI = confidence intervals; IPSS = International Prostate Symptom Score; NR = not reported.
Downgraded based on the following:
a
Very wide confidence interval and few events.